Provided by Tiger Trade Technology Pte. Ltd.

DOGWOOD THERAPEUTICS INC

1.94
+0.06003.19%
Pre-market: 2.040.1000+5.15%09:01 EDT
Volume:53.08K
Turnover:100.29K
Market Cap:65.95M
PE:-0.22
High:2.00
Open:1.88
Low:1.83
Close:1.88
52wk High:9.50
52wk Low:1.28
Shares:33.99M
Float Shares:5.81M
Volume Ratio:0.94
T/O Rate:0.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.9478
EPS(LYR):-7.1350
ROE:-47.77%
ROA:-20.83%
PB:0.96
PE(LYR):-0.27

Loading ...

Dogwood completes patient enrollment in Halneuron trial

TIPRANKS
·
24 mins ago

Dogwood Therapeutics Completes Enrollment in Halneuron Phase 2b Chemotherapy-Induced Neuropathic Pain Trial

Reuters
·
39 mins ago

Dogwood Therapeutics - Topline Data from Halneuron Phase 2B Trial Expected in November 2026

THOMSON REUTERS
·
39 mins ago

Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2B Trial

THOMSON REUTERS
·
39 mins ago

Dogwood Therapeutics Highlights Halneuron Phase 2b Data Readout Timeline for Chemotherapy-Induced Neuropathic Pain Program

Reuters
·
Sep 04

Analysts’ Top Healthcare Picks: Dogwood Therapeutics (DWTX), Quoin Pharmaceuticals (QNRX)

TIPRANKS
·
Sep 04

Dogwood Therapeutics to Host Virtual KOL Event on Halneuron for Chemotherapy-Induced Neuropathic Pain

Reuters
·
Aug 17

Analysts Offer Insights on Healthcare Companies: Dogwood Therapeutics (DWTX), Talphera (TLPH) and 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
Aug 14

Dogwood Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

Dogwood Therapeutics Q2 FY26 Net Loss Widens to $11.5 Million

Reuters
·
Aug 13

Dogwood Therapeutics Q2 EPS USD -0.34

THOMSON REUTERS
·
Aug 13

Press Release: Dogwood Therapeutics Announces Second Quarter 2026 Financial Results

Dow Jones
·
Aug 13

Dogwood Therapeutics Inc Expected to Post a Loss of 14 Cents a Share - Earnings Preview

Reuters
·
Aug 07

Dogwood Therapeutics Posts Corporate Presentation on Non-Opioid Pain, Neuropathy Drug Pipeline

Reuters
·
Aug 04

Dogwood Therapeutics Enrolls First 200 Patients in Phase 2b Neuropathic Pain Trial

MT Newswires Live
·
Jul 20

Dogwood enrolls first 200 patients in HAL-CINP trial

TIPRANKS
·
Jul 20

Dogwood Therapeutics Announces Press Release Availability

Reuters
·
Jul 20

Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2B Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026

THOMSON REUTERS
·
Jul 20

Analysts Offer Insights on Healthcare Companies: Celcuity (CELC), Dogwood Therapeutics (DWTX) and Sanofi (OtherSNYNF)

TIPRANKS
·
Jul 06

Dogwood Therapeutics Posts Corporate Presentation on Non-opioid Pain, Neuropathy Drug Pipeline

Reuters
·
Jul 01